Publications by authors named "Lara Felicioni"

Claim this Profile
O
Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
Emanuela D'Angelo, Iñigo Espinosa, Lara Felicioni, Fiamma Buttitta, Jaime Prat

Hum Pathol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
POLE exonuclease domain mutations in endometrial carcinoma: a case report.
Maria Paola Pasciuto, Lara Felicioni, Claudia Zampacorta, Benedetta Ferro, Pietro Di Marino

Pathologica· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report.
Fiamma Buttitta, Pietro Di Marino, Lara Felicioni, Francesca Chiara Primavera, Benedetta Ferro

Pathologica· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network.
Caterina Fumagalli, Elena Guerini-Rocco, Fiamma Buttitta, Pierluigi Iapicca, Wenqi You, Lara Felicioni

J Clin Pathol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of mutations in NSCLC: a new algorithm for patient selection and personalized treatment.
Fiamma Buttitta, Lara Felicioni, Alessia Di Lorito, Alessio Cortellini, Luciana Irtelli

Oncotarget· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments.
Antonio Marchetti, Alessia Di Lorito, Lara Felicioni, Fiamma Buttitta

Oncotarget· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.
Alessio Cortellini, Katia Cannita, Alessandro Parisi, Paola Lanfiuti Baldi, Olga Venditti, Lara Felicioni

Onco Targets Ther· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm.
Antonio Marchetti, Massimo Barberis, Alessia Di Lorito, Maria Vittoria Pace, Chiara Di Lisio, Lara Felicioni

JCO Precis Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays.
Antonio Marchetti, Maria Vittoria Pace, Alessia Di Lorito, Sara Canarecci, Lara Felicioni

Lung Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Antonio Marchetti, Alessia Di Lorito, Maria Vittoria Pace, Manuela Iezzi, Lara Felicioni

J Thorac Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Antonio Marchetti, Maela Del Grammastro, Lara Felicioni, Sara Malatesta, Giampaolo Filice

PLoS One· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.
Antonio Marchetti, John F Palma, Lara Felicioni, Tommaso M De Pas, Rita Chiari

J Thorac Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer.
Giampietro Gasparini, Fiamma Buttitta, Mario Rosario D'Andrea, Salvatore Tumolo, Angela Buonadonna, Lara Felicioni

Neoplasia· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.
Fiamma Buttitta, Lara Felicioni, Maela Del Grammastro, Giampaolo Filice, Alessia Di Lorito

Clin Cancer Res· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.
Antonio Marchetti, Maela Del Grammastro, Giampaolo Filice, Lara Felicioni, Giulio Rossi

PLoS One· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.
Michele Milella, Carmen Nuzzo, Emilio Bria, Isabella Sperduti, Paolo Visca, Lara Felicioni

J Thorac Oncol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A unique microRNA signature associated with plaque instability in humans.
Francesco Cipollone, Lara Felicioni, Riccardo Sarzani, Sante Ucchino, Francesco Spigonardo

Stroke· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Antonio Marchetti, Lara Felicioni, Sara Malatesta, Maria Grazia Sciarrotta, Luigi Guetti

J Clin Oncol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
Francesca Molinari, Lara Felicioni, Michela Buscarino, Sara De Dosso, Fiamma Buttitta

Clin Cancer Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Antonio Marchetti, Michele Milella, Lara Felicioni, Federico Cappuzzo, Luciana Irtelli

Neoplasia· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer.
Asha Balakrishnan, Junia Y Penachioni, Simona Lamba, Fonnet E Bleeker, Carlo Zanon, Lara Felicioni

Hum Mutat· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational profile of GNAQQ209 in human tumors.
Simona Lamba, Lara Felicioni, Fiamma Buttitta, Fonnet E Bleeker, Sara Malatesta

PLoS One· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway.
Francesca Mancini, Giusy Di Conza, Marsha Pellegrino, Cinzia Rinaldo, Andrea Prodosmo, Lara Felicioni

EMBO J· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
Federico Cappuzzo, Antonio Marchetti, Margaret Skokan, Elisa Rossi, Sujatha Gajapathy, Lara Felicioni

J Clin Oncol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
Fonnet E Bleeker, Simona Lamba, Sieger Leenstra, Dirk Troost, Theo Hulsebos, Lara Felicioni

Hum Mutat· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis